このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行性または転移性非小細胞肺がんの参加者におけるAZD2936の安全性と有効性を評価するための研究 (ARTEMIDE-01)

2026年11月9日 更新者:AstraZeneca

進行性または転移性非小細胞肺癌の参加者におけるAZD2936抗TIGIT /抗PD-1抗体の安全性、薬物動態、薬力学、および有効性を評価するための第I / II相、非盲検、用量漸増および用量拡大試験

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

調査の概要

状態

積極的、募集していない

介入・治療

詳細な説明

This is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of rilvegostomig (AZD2936) in adult participants with stage III unresectable or stage IV NSCLC. The study includes 4 parts: Part A (dose escalation) and Parts B-E (dose expansion).

研究の種類

介入

入学 (実際)

212

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • Research Site
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • Research Site
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • Research Site
      • Groningen、オランダ、9713 GZ
        • Research Site
      • Leiden、オランダ、2333 ZA
        • Research Site
      • Utrecht、オランダ、3584 CX
        • Research Site
      • Melbourne、オーストラリア、3000
        • Research Site
      • Tbilisi、グルジア、0112
        • Research Site
      • Barcelona、スペイン、08035
        • Research Site
      • Madrid、スペイン、28041
        • Research Site
      • Madrid、スペイン、28027
        • Research Site
      • Bangkok、タイ、10700
        • Research Site
      • Chanthaburi、タイ、22000
        • Research Site
      • Muang、タイ、50200
        • Research Site
      • Copenhagen、デンマーク、2100
        • Research Site
      • Dijon、フランス、21079
        • Research Site
      • Toulouse、フランス、31059
        • Research Site
      • Florianópolis、ブラジル、88034-000
        • Research Site
      • Natal、ブラジル、59075-740
        • Research Site
      • Porto Alegre、ブラジル、90035903
        • Research Site
      • Rio de Janeiro、ブラジル、20231-050
        • Research Site
      • São Paulo、ブラジル、01246-000
        • Research Site
      • Anderlecht、ベルギー、1070
        • Research Site
      • Leuven、ベルギー、3000
        • Research Site
      • Kuala Lumpur、マレーシア、59100
        • Research Site
      • Kuching、マレーシア、93586
        • Research Site
      • Chisinau、モルドバ、MD-2025
        • Research Site
      • Chengdu、中国、610041
        • Research Site
      • Chongqing、中国、400030
        • Research Site
      • Taichung、台湾、40705
        • Research Site
      • Taichung、台湾、40201
        • Research Site
      • Tainan、台湾、70403
        • Research Site
      • Taipei、台湾、110
        • Research Site
      • Kashiwa、日本、227-8577
        • Research Site
      • Niigata、日本、951-8566
        • Research Site
      • Sendai、日本、981-0914
        • Research Site
      • Tokyo、日本、104-0045
        • Research Site
      • Seoul、韓国、03722
        • Research Site
      • Seoul、韓国、05505
        • Research Site
      • Seoul、韓国、03082
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~130年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Written informed consent
  • Aged 18 or above
  • Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.
  • Documented PD-L1 expression by PD-L1 IHC per local report.
  • Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
  • Part C and Part D: No prior I/O treatment for metastatic NSCLC.
  • Part E: No prior treatment for metastatic NSCLC.
  • ECOG performance status of 0 or 1 at enrolment.
  • Life expectancy of ≥ 12 weeks at enrolment.
  • Have at least 1 measurable lesion per RECIST v1.1.
  • Adequate bone marrow, liver and kidney function

Exclusion Criteria:

  • Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
  • Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
  • Previous treatment with an anti-TIGIT therapy
  • Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
  • Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
  • Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted).

Treatment with one previous systemic chemotherapy will be allowed.

  • Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.
  • Symptomatic central nervous system (CNS) metastasis.
  • Thromboembolic event within 3 months prior to enrolment.
  • Other invasive malignancy within 2 years prior to screening.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)

Rilvegostomig Intravenous (IV) monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

他の名前:
  • リルヴェゴストミグ
実験的:Dose Expansion Part B: CPI experienced NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

他の名前:
  • リルヴェゴストミグ
実験的:Dose Expansion Part C: CPI Naive NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

他の名前:
  • リルヴェゴストミグ
実験的:Dose Expansion Part D: CPI Naive NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

他の名前:
  • リルヴェゴストミグ
実験的:Dose Expansion Part E: treatment Naive Squamous NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

他の名前:
  • リルヴェゴストミグ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters
時間枠:Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig

A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.

Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
Rate of rilvegostomig discontinuation due to toxicity
時間枠:Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)

Percentage of participants with AEs leading to discontinuation of rilvegostomig

Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
Objective Response Rate (ORR)
時間枠:Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)

Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1

Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)

二次結果の測定

結果測定
メジャーの説明
時間枠
ORR
時間枠:Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

Percentage of participants with a confirmed CR or PR according to RECIST v1.1

Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
Disease control rate (DCR)
時間枠:Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).

Percentage of participants who have a best objective response of confirmed CR or PR or who have SD lasting for at least a certain time of period after start of treatment

Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
Duration of response (DoR)
時間枠:Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

The time from first response according to RECIST v1.1 until progression or death in the absence of disease progression

Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
Durable response rate (DRR)
時間枠:Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

The percentage of participants according to RECIST v1.1 with a confirmed CR or PR lasting 6 months or more

Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
Progression-free survival (PFS)
時間枠:Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).

The time from first dose of study intervention until the date of objective disease progression or death in the absence of disease progression

Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
Measure the receptor occupancy (RO) of TIGIT and PD-1 on peripheral blood
時間枠:Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.

Evaluation of the target engagement of rilvegostomig in peripheral blood

Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.
PK of rilvegostomig: Maximum plasma concentration of the study drug (Cmax)
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Maximum observed plasma concentration of rilvegostomig

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
PK of rilvegostomig: Area under the concentration-time curve (AUC)
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Area under the plasma concentration-time curve

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
PK of rilvegostomig: Clearance
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

A pharmacokinetic measurement of the volume of plasma from which the study intervention is completely removed per unit time.

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
PK of rilvegostomig: Terminal elimination half-life (t 1/2)
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Terminal elimination half life

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
Incidence of anti-drug antibodies (ADA) against rilvegostomig in serum
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Immunogenicity of rilvegostomig

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年9月14日

一次修了 (推定)

2028年6月1日

研究の完了 (推定)

2028年6月1日

試験登録日

最初に提出

2021年7月16日

QC基準を満たした最初の提出物

2021年7月29日

最初の投稿 (実際)

2021年8月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD 共有時間枠

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有アクセス基準

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する